Gabriele Calaminus

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan et al. · European Journal of Cancer · 2019 · 700 citations · Full text

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Neyssa Marina, Sigbjørn Smeland, Stefan Bielack et al. · The Lancet Oncology · 2016 · 511 citations · Full text

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 412 citations · Full text

SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease

Gabriele Calaminus, Rolf‐Dieter Kortmann, Jennifer Worch et al. · Neuro-Oncology · 2013 · 362 citations · Full text

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Jeremy Whelan, Stefan Bielack, Neyssa Marina et al. · Annals of Oncology · 2014 · 321 citations · Full text